The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) requests public comments to inform the future organization of the Sentinel System.
Note: There have been new actions to this contract opportunity. To view the most recent action, please click here.
General Information
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Nov 01, 2022 02:35 pm EDT
- Original Response Date: Dec 12, 2022 02:00 pm EST
- Inactive Policy: 15 days after response date
- Original Inactive Date:
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code: B537 - SPECIAL STUDIES/ANALYSIS- MEDICAL/HEALTH
- NAICS Code:
- 54171 - Research and Development in the Physical, Engineering, and Life Sciences
- Place of Performance: Silver Spring , MD 20903USA
Description
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) requests public comments to inform the future organization of the Sentinel System. FDA seeks information that will assist in the exploration of alternative approaches to meet FDA’s legal requirements and fulfill its public health mission by adding value to the Sentinel System. Specifically, FDA is interested in organizational capabilities that will support the development of an efficient and economical product safety surveillance system that is not limited to the use of a common data model and a distributed data partners network and instead leverages multiple technical approaches.
See Attachment for RFI.
Attachments/Links
Contact Information
Contracting Office Address
- 10903 New Hampshire Avenue
- Silver Spring , MD 20993
- USA
Primary Point of Contact
- Howard S. Yablon
- howard.yablon@fda.hhs.gov
Secondary Point of Contact
History
- Dec 27, 2022 11:56 pm ESTSpecial Notice (Updated)
- Nov 01, 2022 02:35 pm EDTSpecial Notice (Original)